It has been reported that IDO inhibitor combine with taxane augmented tumor-infiltrating lymphocytes to kill tumor cells and improve clinical outcomes in BC patients [271], since pro-inflammatory molecules such as IL-1, IL-6, and IFN induce expression of IDO through STAT independent pathway involving P38, MAPK, and NF-kβ [272] and these cytokines and signaling pathways are inhibited by TQ [185,273,274], so that IDO will be another potential target site for TQ. Here, IDO1 is linked to breast cancer.